Interestingly, further studies have shown that CD44 can act to limit drug sensitivity in prostate cancer cells [17] and in clinical ovarian cancer [18] but a relationship between CD44 and endocrine response in breast cancer has not yet been reported. The gene discussed is CD44; the disease is ovarian carcinoma.